CureVac stock gains as COVID vaccine candidates show promise

CureVac N.V. shares (CVAC) gained 3% premarket on Friday as the company released new data from a trial of its mRNA COVID-19 vaccine candidates, which it is developing in collaboration with GSK PLC (GSK). An investigational monovalent shot as well as a bivalent vaccine candidate successfully boosted antibody levels and were generally well tolerated across dosages, CureVac said in a release. All three dose levels tested were below those used in mRNA-based COVID vaccines currently licensed in the U.S. and European Union, the company said. CureVac said it is in "advanced discussions" with regulators to chart a path for a phase 3 study of the vaccine candidates. If approved, the shots would compete with mRNA Covid vaccines already available from Moderna Inc. (MRNA) and Pfizer Inc. (PFE). CureVac shares are down 34% over the past 12 months, while the S&P 500 has gained 23%. GSK's American depositary receipts fell 0.5% premarket on Friday and have gained 13.3% over the past 12 months.

-Eleanor Laise

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

01-05-24 0759ET

Copyright (c) 2024 Dow Jones & Company, Inc.